A year for change

Article

2009 has started with a bang...

2009 has started with a bang. Less than two weeks into the New Year, a shock announcement came from global healthcare and medical device firm Abbott, as it publicized its acquisition of AMO. For Abbott, the acquisition will see the addition of a brand new business division to its extensive medical device portfolio, allowing it to gain a brand new customer base and to further diversify risk; undeniably a positive move, particularly in these uncertain economic conditions. The purchase will also catapult Abbott into a leading position within the global ophthalmic market, which is previously unchartered territory for the company. For AMO, Abbott offers strong financial support as well as a new perspective for growth and expansion strategies. AMO can also capitalize on the healthcare firm’s strong reputation and global presence in international markets. So could this $2.8 billion deal spell the first in a long line of acquisitions for 2009? I think so!

Change has also been the theme for Ophthalmology Times Europe as we kick off 2009. Okay, so maybe the scale of our changes cannot quite match those of the AMO acquisition but you may have noticed that the look, size and style of this issue of your magazine have changed, we hope, to better suit your needs. Please do feel free to contact us if you would like to make any suggestions or comments.

I would now like to take this opportunity to wish you all a very happy New Year. May 2009 bring you good health, success, and continued enjoyment from your monthly edition of Ophthalmology Times Europe!

Fedra Pavloufpavlou@advanstar.com

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.